Compare INKT & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INKT | OFS |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 54.3M |
| IPO Year | 2021 | 2010 |
| Metric | INKT | OFS |
|---|---|---|
| Price | $12.70 | $3.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $39.00 | N/A |
| AVG Volume (30 Days) | 12.4K | ★ 71.1K |
| Earning Date | 11-13-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 18.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.48 | $2.72 |
| 52 Week High | $16.00 | $7.81 |
| Indicator | INKT | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 43.87 |
| Support Level | $10.84 | $3.53 |
| Resistance Level | $13.40 | $4.00 |
| Average True Range (ATR) | 0.61 | 0.13 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 83.87 | 13.04 |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.